Solaris Biotech and Wildtype Announce Agreement for Large-scale Bioreactors for Cultivated Seafood Production

Rhea-AI Summary

Solaris Biotech has partnered with Wildtype to develop advanced bioreactors aimed at enhancing large-scale production of cultivated seafood. This collaboration responds to the growing global demand for seafood, projected to increase by 23 million tons by 2030. Solaris, part of Donaldson Company (NYSE: DCI), specializes in bioreactor technology, positioning itself at the forefront of the alternative proteins market. Both companies aim to make cultivated seafood more affordable while providing sustainable options that avoid contaminants found in traditional fish.

Positive

• Partnership with Wildtype enhances Solaris' position in the growing cultivated seafood market.
• Development of advanced bioreactors targets a projected seafood consumption increase of 23 million tons by 2030.

Negative

• None.

• Solaris and Wildtype signed an agreement to collaboratively develop a new generation of bioreactors to foster large-scale production of cultivated seafood.
• Bioreactors are one of the most important pieces of equipment in the productive infrastructure of cell-cultured food proteins and new cultivated food technologies.

PORTO MANTOVANO, Italy--(BUSINESS WIRE)-- Donaldson brand Solaris Biotech, a leading innovator and manufacturer of bioreactors, fermenters and tangential flow filtration systems has entered an agreement with Wildtype, a San Francisco-based company focused on creating cultivated seafood. The two companies will engage in a collaborative development program to design a next generation family of bioreactor systems to help meet the growing demand for seafood.

Solaris Industrial Scale Bioreactor Systems. (Photo: Business Wire)

Food is fundamental to our existence, and food demand is increasing with rising income levels and a multiplying global population. Alternative proteins are experiencing rapid growth as a result of these trends, and cell cultivated proteins are at the forefront of these innovations. “Solaris, with our specialized bioprocessing equipment, is uniquely positioned to play a significant role in the advancement of new cultured food technologies,” said Matteo Brognoli, Managing Director of Solaris. “Alternative proteins have become the fastest growing segment for bioreactor systems and we are proud that our cultivators are the enabling technology for this leap in the food industry.”

“Wildtype is on a mission to produce the cleanest, most delicious seafood on the planet,” said Justin Kolbeck, Wildtype CEO. “Annual global seafood consumption is expected to increase an additional 23 million tons by 2030 and one of the most important pieces in the productive infrastructure are the cultivators used to grow cells. With Solaris’ technologically advanced solutions we have found the right partner to help us scale and make our products more affordable and accessible.”

About Solaris

Solaris, a Donaldson brand, is a leading innovator and manufacturer of fermenters, bioreactors, tangential flow (TFF) and depth (FFF) filtration systems used for a variety of applications in the pharmaceutical, biopharmaceutical and food industries. Its product and development teams create solutions at all scales, from benchtop R&D systems to complete engineered solutions tailored to individual customer needs. Since November 2021, Solaris has been a part of Donaldson Company (NYSE: DCI) and its expansion into life sciences. Discover the full scope of Solaris products and capabilities at solarisbiotech.com.

About Wildtype

Wildtype is on a mission to create the cleanest, most sustainable seafood on the planet, starting with sushi-grade salmon. The company is pioneering cellular agriculture to protect wild species and our oceans, and to reverse trends of global food insecurity. Wildtype will provide consumers with a new option for real seafood that provides the same nutritional benefits as the most pristine wild-caught fish, without common contaminants such as mercury, microplastics, antibiotics or pesticides.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006265/en/

Primary contact:

Becky Cahn (+1 952.703.4590)

Corporate.Communications@Donaldson.com

Secondary contact (Italian inquiries):

Raffaello Porro (+393351015456)

Raffaello.porro@studiorpr.com

Source: Donaldson

FAQ

What is the recent partnership between Solaris and Wildtype about?

Solaris and Wildtype have signed an agreement to develop advanced bioreactors for large-scale production of cultivated seafood.

How does the partnership affect Solaris (DCI)?

The partnership positions Solaris to capitalize on the growing demand for alternative proteins, potentially boosting revenue and market presence.

What is the market demand for seafood expected to increase by 2030?

Annual global seafood consumption is projected to increase by 23 million tons by 2030.

What role do bioreactors play in cultivated seafood production?

Bioreactors are essential for producing cell-cultured food proteins and are key to the infrastructure of cultivated food technologies.